NHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, Hunan, China.
Cell Oncol (Dordr). 2024 Oct;47(5):1579-1592. doi: 10.1007/s13402-024-00975-1. Epub 2024 Aug 12.
Tertiary lymphoid structures (TLSs) are ectopic lymphoid aggregates formed by the structured accumulation of immune cells such as B cells and T cells in non-lymphoid tissues induced by infection, inflammation, and tumors. They play a crucial role in the immune response, particularly in association with tumor development, where they primarily exert anti-tumor immune functions during tumorigenesis. Current research suggests that TLSs inhibit tumor growth by facilitating immune cell infiltration and are correlated with favorable prognosis in various solid tumors, serving as an indicator of immunotherapy effectiveness to some extent. Therefore, TLSs hold great promise as a valuable biomarker. Most importantly, immunotherapies aimed to prompting TLSs formation are anticipated to be potent adjuncts to current cancer treatment. This review focuses on the formation process of TLSs and their potential applications in cancer therapy.
三级淋巴结构 (TLSs) 是由感染、炎症和肿瘤等因素诱导的非淋巴组织中免疫细胞（如 B 细胞和 T 细胞）的有序聚集形成的异位淋巴聚集物。它们在免疫反应中起着至关重要的作用，特别是与肿瘤的发展有关，在肿瘤发生过程中，它们主要发挥抗肿瘤免疫功能。目前的研究表明，TLS 通过促进免疫细胞浸润来抑制肿瘤生长，并且与各种实体瘤的良好预后相关，在某种程度上可作为免疫治疗效果的指标。因此，TLS 有望成为一种有价值的生物标志物。最重要的是，旨在促进 TLS 形成的免疫疗法有望成为当前癌症治疗的有力辅助手段。本综述重点介绍了 TLS 的形成过程及其在癌症治疗中的潜在应用。
